進行精巣腫瘍に対する大量化学療法

HANDLE Web Site オープンアクセス
  • 三宅, 秀明
    神戸大学大学院医学研究科外科系講座腎泌尿器科学分野
  • 藤澤, 正人
    神戸大学大学院医学研究科外科系講座腎泌尿器科学分野

書誌事項

タイトル別名
  • High-Dose Chemotherapy for Advanced Testicular Germ Cell Tumors
  • シンコウセイソウ シュヨウ ニ タイスル タイリョウ カガク リョウホウ

この論文をさがす

抄録

Since the introduction of cisplatin, the therapeutic outcome of patients with testicular germ cell tumors (TGCT) has markedly improved. Therefore, even advanced disease may be completely cured by an appropriate multidisciplinary therapy. However, approximately 20-30% of advanced TGCT patients could not be cured by induction therapy. In order to improve the prognosis for such poor-risk patients, several therapeutic modalities have been investigated, including high-dose chemotherapy (HDCT) combined with peripheral blood stem cell transplantation. The application of HDC to TGCT may be due to several reasons suchas younger age of TGCT patients, smoothrecovery from myelosuppression following chemotherapy and high sensitivity to chemotherapeutic agents. Although in a non-randomized study, the outcome of HDCT, particularly recurrence-free survival, seemed to be more favorable than that of conventional regimens, suchas bleomycine, etoposide and cisplatin and etoposide, ifosfamide and cisplatin, recently conducted randomized trials failed to demonstrate the usefulness of HDCT compared with the conventional regimen in both induction and salvage settings. Considering these findings in addition to the recent development of promising novel agents, it is reasonable to regard induction as well as salvage HDCTs as recommendation grade C in the guideline published by Japanese Urological Association.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 58 (12), 731-735, 2012-12

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ